ArticleDiscover oncology2025
Interfered long non-coding RNA HELLPAR or up-regulated microRNA-448 inhibits nasopharyngeal carcinoma progression via suppression of ADAM10.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Analysis of the LncRNA-Mediated ceRNA Network Associated With Prognosis in Posttreatment Recurrent Nasopharyngeal Carcinoma.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNasopharyngeal carcinoma (NPC) is a highly invasive malignancy with poor prognosis, necessitating further exploration of its molecular mechanisms. While HELLP-associated long non-coding RNA (HELLPAR), microRNA-448 (miR-448), and a disintegrin and metalloprotease 10 (ADAM10) have been implicated in other malignancies, their regulatory interplay and functional roles in NPC remain unclear. This study aimed to investigate the role of HELLPAR in NPC progression through its interaction with miR-448 and ADAM10.
methodsCancerous and adjacent non-cancerous tissues were collected from 53 NPC patients admitted to our hospital between 1st January 2018 and 1st January 2020. Transcript levels of HELLPAR, miR-448, and ADAM10 were measured using quantitative real-time PCR (RT-qPCR), while the protein expression levels of ADAM10 were assessed by Western blotting. Long-term survival data were analyzed to assess the correlation between HELLPAR expression and patient prognosis. The binding interactions of HELLPAR/miR-448 and miR-448/ADAM10 were predicted and experimentally validated. Overexpression and knockdown constructs for HELLPAR, miR-448, and ADAM10 were transfected into NPC cells to assess their effects on proliferation, invasion, and apoptosis.
resultsHELLPAR and ADAM10 were significantly upregulated at both the RNA and protein levels in NPC tissues and cells, while miR-448 was notably downregulated. Suppression of HELLPAR inhibited NPC cell proliferation and invasion while promoting apoptosis. Mechanistically, HELLPAR functioned as a competitive endogenous RNA (ceRNA) by binding to miR-448, thereby downregulating its RNA expression. Overexpression of miR-448 counteracted the tumor-promoting effects of HELLPAR. Additionally, miR-448 directly targeted and suppressed ADAM10. Overexpression of ADAM10 reversed the inhibitory effects of miR-448 on NPC cell proliferation and invasion.
conclusionThe HELLPAR/miR-448/ADAM10 axis plays a critical role in NPC progression. Suppressing HELLPAR expression enhances miR-448 activity, which in turn downregulates ADAM10 at both RNA and protein levels, leading to reduced NPC cell proliferation and invasion while promoting apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.